Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Net Income (2016 - 2025)

Historic Net Income for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$3.4 million.

  • Lineage Cell Therapeutics' Net Income fell 1396.2% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.0 million, marking a year-over-year decrease of 5974.76%. This contributed to the annual value of -$18.6 million for FY2024, which is 1348.76% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Net Income of -$3.4 million as of Q3 2025, which was down 1396.2% from -$19.3 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Net Income ranged from a high of -$1.4 million in Q1 2021 and a low of -$28.0 million during Q4 2021
  • For the 5-year period, Lineage Cell Therapeutics' Net Income averaged around -$7.2 million, with its median value being -$6.0 million (2025).
  • Over the last 5 years, Lineage Cell Therapeutics' Net Income had its largest YoY gain of 8281.92% in 2021, and its largest YoY loss of 294644.31% in 2021.
  • Lineage Cell Therapeutics' Net Income (Quarter) stood at -$28.0 million in 2021, then skyrocketed by 77.29% to -$6.4 million in 2022, then increased by 25.9% to -$4.7 million in 2023, then surged by 31.06% to -$3.2 million in 2024, then fell by 5.23% to -$3.4 million in 2025.
  • Its Net Income was -$3.4 million in Q3 2025, compared to -$19.3 million in Q2 2025 and -$6.0 million in Q1 2025.